- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma, Relistor (methylnaltrexone bromide) / Ono Pharma, Bausch Health
Review, Journal: Antagonists of the Mu-Opioid Receptor in the Cancer Patient: Fact or Fiction? (Pubmed Central) - Sep 20, 2022
We have found studies related to methylnaltrexone (MNTX) and naltrexone (NTX) usage in cancer outcomes-related setting...However, clinical results are scarce and limited to poor-quality evidence. Further high-quality studies are warranted to study antagonists of mu-opioid receptor role as a therapeutic option in different types of cancer, especially in patients where the classical treatment causes unacceptable side effects.
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Low dose naltrexone (Twitter) - Sep 13, 2022
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Enrollment closed, Trial completion date, Trial primary completion date: Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome (clinicaltrials.gov) - Sep 7, 2022
P2, N=60, Active, not recruiting,
Further high-quality studies are warranted to study antagonists of mu-opioid receptor role as a therapeutic option in different types of cancer, especially in patients where the classical treatment causes unacceptable side effects. Recruiting --> Active, not recruiting | Trial completion date: Mar 2022 --> Nov 2022 | Trial primary completion date: Mar 2022 --> Nov 2022
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
A Case of Cholestatic Drug-Induced Liver Injury After Ashwagandha Root Supplementation (Crown Ballroom) - Sep 4, 2022 - Abstract #ACG2022ACG_3206;
He was discharged with prn hydroxyzine for itching and told his DILI would resolve with time...He was treated with cholestyramine, ursodiol and antihistamines...Was also started on low dose naltrexone, and discharged...He was started on low dose rifampin given persistent pruritus, with mild improvement, and ultimately discharged with close follow-up...This case report further re-enforces the importance of careful monitoring and awareness of our patients’ supplemental health products. Table: Bilirubin and symptoms trend
- |||||||||| Importance of Bifidobacteria in Crohn’s Disease (Crown Ballroom) - Sep 4, 2022 - Abstract #ACG2022ACG_1981;
Medications included Humira, Stelara, Remicade, Methotrexate, Enteragam, prednisone, low dose naltrexone, Entevio). Relative Abundance of Bifidobacterium levels significantly decreased in untreated symptomatic Crohn’s patients vs. control ( p< 0.0001) and in untreated symptomatic vs. treated asymptomatic ( p = 0.0006).
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Enrollment change, Trial withdrawal: Immune Effects of Low-dose Naltrexone in ME/CFS (clinicaltrials.gov) - Sep 2, 2022
P=N/A, N=0, Withdrawn,
Relative Abundance of Bifidobacterium levels significantly decreased in untreated symptomatic Crohn’s patients vs. control ( p< 0.0001) and in untreated symptomatic vs. treated asymptomatic ( p = 0.0006). N=30 --> 0 | Suspended --> Withdrawn
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
L109. Select Opioid Partial Agonist or Antagonist for Refractory Spine, Body and Joint Pain. Which Alternative Versus Opioid Full Agonist Will Be a Better Choice? (LaNouvelle Ballroom A) - Aug 15, 2022 - Abstract #ASA2022ASA_476;
Review classification of opioid receptors, agoists, and antagonists Summarize the proposed mechanism of action on Low Dose Naltrexone (LDN) Describe clinical efficacy of LDN in chronic diffuse spine, body and joint pain Interpret the current diagnostic criteria of Fibromyalgia Appraise indication of LDN as part of ultimodal analgesia in fibromyalgia Review classification of opioid receptors, agoists, and antagonists Summarize the proposed mechanism of action on Low Dose Naltrexone (LDN) Describe clinical efficacy of LDN in chronic diffuse spine, body and joint pain Interpret the current diagnostic criteria of Fibromyalgia Appraise indication of LDN as part of ultimodal analgesia in fibromyalgia
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Journal: Thyroid, Diet, and Alternative Approaches. (Pubmed Central) - Aug 12, 2022
While many patients are seeking to avoid conventional therapy and instead turn to alternative and dietary approaches to thyroid disease management, many of the most popular approaches have no proven benefit or have not been well-studied. It is our responsibility to educate our patients about the evidence for or against benefit, potential harms, or dearth of knowledge behind these strategies.
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Trial completion date, Trial primary completion date: Low-dose Naltrexone for Bladder Pain Syndrome (clinicaltrials.gov) - Jul 12, 2022
P2, N=40, Recruiting,
Randomised control trials are needed to further explore this. Trial completion date: Feb 2023 --> Oct 2023 | Trial primary completion date: Aug 2022 --> Jul 2023
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Low dose naltrexone (Twitter) - Jul 4, 2022
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Low dose naltrexone (Twitter) - Jun 22, 2022
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Journal: Repurposing low-dose naltrexone (LDN) for the prevention and treatment of immunothrombosis in COVID-19. (Pubmed Central) - Jun 11, 2022
Mechanistically, LDN can blunt innate immune responses and Toll-like receptor (TLR) signaling, reducing interleukin1 (IL-1), tumor necrosis factor-alpha (TNF-α), and interferon (IFN) levels. Because of the immune-mediated thrombotic mechanisms that underlie COVID-19, we hypothesize that the immune-modulating and known pharmacologic properties of LDN could be leveraged as a novel therapeutic strategy in COVID-19.
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Journal: The State-of-the-art Pharmacotherapeutic Options for the Treatment of Chronic Non-Cancer Pain. (Pubmed Central) - May 25, 2022
Furthermore, they provide developing evidence on more novel pharmacotherapeutics including alpha lipoic acid, acetyl-L-carnitine, low-dose naltrexone, calcitonin gene-related peptide antagonists, targeted toxin therapy, Nav1.7 inhibitors, neurotensin agonists, purinoceptor antagonists, and sigma-1 receptor antagonists...Current guidelines recommend a personalized approach to the chronic pain treatment, in each case accounting for type, location, severity, and chronicity of pain. Clinicians should also carefully consider the risk-to-benefit ratio to the patient based on the drug side effect profile, patient age, and comorbidities.
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Trial completion date, Trial primary completion date: LDN-CRPS: Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome (clinicaltrials.gov) - May 24, 2022
P=N/A, N=40, Recruiting,
Clinicians should also carefully consider the risk-to-benefit ratio to the patient based on the drug side effect profile, patient age, and comorbidities. Trial completion date: Jun 2022 --> Jun 2023 | Trial primary completion date: Jun 2022 --> Jun 2023
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Enrollment open, Trial completion date, HEOR: INNOVA: Cost-utility and Physiological Effects of LDN in Patients With Fibromyalgia (clinicaltrials.gov) - May 9, 2022
P4, N=120, Enrolling by invitation,
Trial completion date: Jun 2022 --> Jun 2023 | Trial primary completion date: Jun 2022 --> Jun 2023 Not yet recruiting --> Enrolling by invitation | Trial completion date: Jul 2024 --> Dec 2024
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Complementary and alternative medicine use and recommendations for discontinuation of supplements in an integrative oncology clinic. (Available On Demand; 304) - Apr 28, 2022 - Abstract #ASCO2022ASCO_866;
Cancer patients both on and off active treatment are using large numbers of DS with potential for adverse effects and/or decreasing efficacy of treatments. This study highlights the prevalence of DS and alternative medicine usage in cancer patients referred to an integrative oncology clinic and demonstrates the need for counseling about safe supplement use; in 35% of patients, discontinuation of DS was recommended.
- |||||||||| naltrexone / Generic mfg.
Journal: Naltrexone at low doses (LDN) and its relevance to cancer therapy. (Pubmed Central) - Apr 27, 2022
Naltrexone was designed to inhibit opioid receptors without activating them and hence used to block the stimulatory effects of morphine and heroin...Considering the increase in number of anecdotal reports of activity, there will likely be a bigger drive towards using LDN in the oncological setting. These reports support clinical trials of LDN in cancer, especially when given in combination with certain chemotherapy.
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Trial completion date, Trial primary completion date: IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone (clinicaltrials.gov) - Apr 6, 2022
P4, N=44, Recruiting,
Low dose naltrexone (3mg) failed to improve the severity of the LPP more than what is achievable with topical clobetasol. Trial completion date: Jun 2022 --> Jun 2023 | Trial primary completion date: Dec 2021 --> Dec 2022
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Review, Journal: A Narrative Review of Therapies for Scalp Dermatomyositis. (Pubmed Central) - Apr 2, 2022
Though the literature was not systematically assesed in this review, these findings illustrate not only that strategies for refractory scalp DM are lacking, but also that those demonstrating potential efficacy are limited by low levels of evidence. Additional studies, especially randomized controlled trials, are needed to better inform management of scalp DM.
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Preclinical, Journal: Timing of treatment with an endogenous opioid alters immune response and spinal cord pathology in female mice with experimental autoimmune encephalomyelitis. (Pubmed Central) - Apr 1, 2022
Therapeutic paradigms of exogenous opioid growth factor (OGF) or low-dose naltrexone (LDN) treatment can modulate EAE, but little is reported regarding OGF or LDN effects on peripheral inflammation, microglia activation, and/or macrophage proliferation...Both treatment regimens of OGF or LDN reduced activated microglia, whereas only prophylactic treatment prevented CNS macrophage aggregation. These data demonstrate that the timing of LDN or OGF treatment initiation alters outcomes and can prevent or reverse behavioral deficits, cytokine activation, and spinal cord pathology.
|
